Prognosis in UC After First Biological
Condition: Ulcerative Colitis Intervention: Biological: infliximab, adalimumab, golimumab, vedolizumab, ustekinumab Sponsor: Tampere University Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials